Nuochengjianhua announced today that the phase I clinical trial targeting TL1a and IL-23p19 novel bispecific antibody ICP-B161, which was independently developed by the company, has completed the enrollment of the first test subjects and is intended to treat autoimmune diseases such as inflammatory bowel disease.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.